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Abstract: The Hepatitis C virus causes chronic infections in humans, which can 
develop to liver cirrhosis and hepatocellular carcinoma. The Bovine viral diarrhea virus 
is used as a surrogate model for antiviral assays for the HCV. From marine invertebrates 
and microorganisms isolated from them, extracts were prepared for assessment of their 
possible antiviral activity. Of the 128 tested, 2 were considered active and 1 was 
considered promising. The best result was obtained from the extracts produced from the 
Bacillus sp. isolated from the sponge Petromica citrina. The extracts 555 (500 µg/mL, 
SI>18) and 584 (150 µg/mL, SI 27) showed a percentage of protection of 98% against 
BVDV, and the extract 616, 90% of protection. All of them showed activity during the 
viral adsorption. Thus, various substances are active on these studied organisms and 
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may lead to the development of drugs which ensure an alternative therapy for the 
treatment of hepatitis C. 
Keywords: hepatitis C virus; antiviral agents; marine microorganisms 
 
1. Introduction 
Viruses cause many important diseases, and viral-induced emerging and re-emerging infectious 
diseases representing a major health threat to the public. Effective control of viral infection has 
remained an unachieved goal, due to virus intracellular replicative nature and readily mutating 
genomes, as well as the limited availability of anti-viral drugs and measures [1]. 
Hepatitis C virus (HCV) infection is a serious global health problem, and the patients with 
chronic infection have risk of developing liver cirrhosis and hepatocellular carcinoma [2]. HCV 
infects as many as 170 million people worldwide, representing 3% of the world’s population [3]. 
The big problem is that, in general, people with chronic hepatitis C are relatively asymptomatic and 
have few if any clinical manifestations prior to the development of cirrhosis [4]. 
Currently, no vaccine exists for hepatitis C vírus [5]. The treatment for HCV infection consists of 
pegylated interferon (IFN)-α in combination with the nucleoside analog ribavirin  
(1-β-D-ribofuranosyl-1,2,4-triaxole-3-carboxamide) [6]. This therapy is expensive, effective in only 
a subset of patients and associated with many side effects [7] such as depression, flu-like symptoms, 
fatigue, and hemolytic anemia, and, due to this, many patients are forced to discontinue therapy [8]. 
Since the discovery of the HCV, its propagation in cell culture has been a major goal for 
virologists worldwide. All human hepatitis viruses are very difficult to grow in cell culture [9]. 
Because of this, another virus is used as a surrogate model for studies regarding HCV. 
The bovine viral diarrhea virus (BVDV), a member of the Flaviviridae family (genus Pestivirus), 
shares similarities with HCV (genus Hepacivirus, Flaviviridae family) in terms of their replication 
cycles, biology and genetic organization, and shows the functionally homologous nature of many of 
their gene products, which are considered to be major targets for the development of anti-HCV 
agents [10].   
BVDV is easy to culture in vitro, molecular clones are available for genetic studies and the virus 
undergoes a complete replication cycle. Both BVDV and HCV utilize the LDL receptor to enter 
cells, use a functionally similar internal ribosome entry site for translation, have a mechanistically 
similar NS5B RNA-dependent RNA polymerase, and a seemingly equivalent mechanism of virion 
maturation, assembly and egress [11]. 
For these reasons, BVDV is considered to be a valuable surrogate virus model for identifying 
and characterizing antiviral agents for use against HCV [11-15].  
Because of the lack of available vaccines and treatments not being tolerated by some patients, 
new antiviral agents to treat HCV infection are desperately needed [11]. 
Natural products derived from terrestrial and marine kingdoms represent an inexhaustible source 
of compounds with promising antiviral action, mainly for the variety of synthesized metabolites. In 
relation to infectious diseases, the exploration of the marine environment represents a promising 
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strategy in the search for active compounds. It is necessary due to the appearance of resistance to 
available treatments in many microorganisms [1]. 
In this study, extracts were tested against BVDV to evaluate their potential antiviral activity. 
2. Materials and Methods 
2.1. Crude Extracts 
 
Extracts derived from the metabolism of the bacteria strain were obtained by the method of 
liquid-liquid separation. A pre-inoculum of the isolates were cultured in 7 mL of isolation medium 
and incubated at 30 °C for 24 h at 100 rpm. After growth of the culture, the total volume was 
transferred to an Erlenmeyer flask containing 50 mL of the same medium and kept at the same 
temperature and rotation for 24 h. Again, 50 mL of bacterial growth were transferred to a glass jar 
containing 500 mL of the same medium and kept in the same conditions mentioned for seven days. 
After this period, 500 mL of ethyl acetate were added and the mixture was triturated in a blender 
with high rotation. Then, the mixture was stirred at 100 rpm for 24 h. 
Initially, the mixture was filtered on Buchner funnel containing a pad of celite and then the 
organic phase was recovered in an Erlenmeyer flask using a separatory funnel. In the aqueous 
phase, the cell debris and the culture medium were retained, and in the organic phase, the possible 
biologically active metabolites were recovered. 
The organic phase was then filtered through cotton and transferred to a round bottom flask. 
Extracts contained in the organic phase were concentrated in rotaevaporador (BuchiRotavapor  
R-215) in vacuum at 37 °C until complete drying of the solvent. Then the extracts were suspended 
in methyl alcohol, filtered with cotton, and the volume transferred to new tubes glass using Pasteur 
pipette. These tubes were led to Savant vacuum centrifuge, model 210A Speedvac ® Plus SC for 
evaporation. After complete drying of the solvent, the extracts were dissolved in 10% DMSO in 
medium AMH and kept at 4 °C until use in the antiviral activity assays. 
 
2.2. Antiviral Activity Assay 
 
2.2.1. Virus and cell lines. 
 
The Madin–Darby bovine kidney (MDBK) cell were propagated in monolayer cultures using 
minimal essential medium (MEM) with Earles’s salts, supplemented with 10% equine serum. Cells 
were passaged at 1:2 to 1:10 dilutions according to conventional procedures using 0.05% trypsin 
with 0.02% EDTA. 
 
2.2.2. Cell cytotoxic effect 
 
100 μL of suspension per well were seeded in 96-well culture plates at a density of  
1 x 105 cells/mL. The microtiter plates containing cells were pre-incubated for 24 h at 37 °C to 
allow stabilizations prior to addition (100 μL) of samples at 11 concentrations (500 to 0,48 μg/mL). 
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The maximum nontoxic concentration (MNTC) was determined microscopically by the observation 
of morphological changes of cells at 24, 48 and 72 h of incubation, and after 72 h the results were 
obtained with MTT assay. 
 
2.2.3. MTT assay 
 
The MTT assay is a sensitive in vitro assay for the measurement of cell proliferation or a 
reduction in cell viability. Cells were cultured in 96-well tissue culture plates. The tetrazolium 
compound MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added to the 
wells and the cells were incubated. MTT is reduced by metabolically active cells to insoluble purple 
formazan dye crystals. Dimethylsulfoxide was then added to the wells, solubilizing the crystals so 
the absorbance could be read using a spectrophotometer on absorbance of 540 nm [16,17]. The data 
was analyzed by plotting cell number versus absorbance, allowing quantitation of changes in cell 
proliferation. The rate of tetrazolium reduction is proportional to the rate of cell proliferation and 
indirectly indicates the reduction in cell viability caused by the action of virus. 
 
2.2.4. Titration of viruses 
 
The cells were seeded in 96-well culture plates at a density of 1 x 105 cells/mL and then 
incubated at 37 º C in a humidified atmosphere containing CO2 for 24 h. Serial dilutions of virus 
stocks were prepared and cells were infected with the dilution of virus. After an additional 
incubation (1–2 days), the cytopathic effect was recorded. The 50% tissue-culture infective dose 
(TCID50) per mL was calculated as described previously by Reed and Münch [18]. 
 
2.2.5. Antiviral activity 
 
Determination of antiviral activity was based on cytopathic effect inhibition. All experiments 
were performed in quadruplicate. Briefly, for evaluation of inhibition, the cells were seeded in  
96-well culture plates. After 24 h of incubation, the medium was replaced with 100 µL of MEM(E) 
containing the extracts at 50 µg/mL, and 50 µL of 100 TCID50/50µL of viruses were added in 
quadruplicate and incubated for 3 days. Controls consisted of untreated infected (virus at  
100 TCID50/50µL), treated noninfected (extract control), and untreated noninfected. The cytophatic 
effect was observed after 72 h and the extracts with antiviral activity were determinate. For 
quantification of this activity, the MTT assay was performed. This assay allows the quantification 
of cell viability and indirectly allows quantification of cell extract protection against the virus. 
The protection percentage was calculated using the following formula [19]: (Absorbance of  
treated – absorbance  of  the  control  virus) / (Absorbance of the cellular control - absorbance of the 
control virus)   X 100. 
The test of antiviral activity was evaluated initially with a single dose at MNTC against  
100 TCID50/mL of virus. The extracts with activity greater than 90% were considered promising.  
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To confirm activity, a concentration response curve with different concentrations of extract in 
the presence of 100 TCID50/mL of virus was determined by MTT assay, to determine antiviral 
concentration 50% (EC50).  
The EC50 were calculated from concentration-effect curves after linear regression analysis. The 
results were obtained from triplicate assays with at least five extract concentrations. The percentage 
of cytotoxicity was calculated as [(A – B)/A] x 100, where A and B are the OD540 of untreated and 
of treated cells, respectively. The percentages of protection were calculated as  
[(A − B) × 100/(C − B)], where A, B and C indicate the absorbance of the extracts, virus and cell 
controls, respectively. Each obtained EC50 value was defined as the effective concentration that 
reduced the absorbance of infected cells to 50% when compared with cell and virus controls. The 
50% inhibition (IC50) for each compound were obtained from dose-effect-curves (not shown) 
generated by plaque assay after linear regression analysis. The EC50 and IC50 are the average of 
three assays with five concentrations within the inhibitory range of the compounds. The therapeutic 
index (i.e., selective index) was defined as EC50/IC50. 
 
2.2.6. The potential stage in the viral infection cycle 
 
Cells and viruses were incubated with active extracts at different stages during the viral infection 
cycle in order to determine the mode of antiviral action. Cells were pretreated with samples before 
viral infection; viruses were incubated with samples before infecting the cells; and the cells were 
infected with the virus and incubated together before the addition of samples. Samples were used at 
the maximum noncytotoxic concentration. Subsequent assays were performed to differentiate the 
active extracts in the pretreatment between adsorption and penetration. 
Values were expressed as titer (TCID50/µL) and inhibition percentage (IP) as described in [20]. 
The inhibition percentage was calculated by the formula: (IP) = (1 – T/C) x 100, where T is the 
antilog of the extract-treated viral titers and C is the antilog of the control (without extract) viral 
titers. IP was considered positive at greater than or equal to 98%. 
 
2.2.7. Virucidal action 
 
In order to evaluate possible extracellular viral inactivation by extracts, equal volumes (100 µL) 
of the 10-fold serially diluted virus suspension and MNTC of the extracts were mixed and incubated 
for 1h at 37 °C. Each mixture was then added to the cell monolayer, and infectious titers were 
compared with controls. 
 
2.3. Statistical analysis 
 
The results were expressed as mean ± s.e.m. The selectivity index (SI) was determined by the 
ratio of CC50 to EC50. The statistically different effects of tested extracts on the inhibition of virus 
replication were compared with the control group using the Student’s t-test with p≤0.05 for 
significant result.  
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2.4. Identification of bacteria by 16S rRNA gene sequencing analysis 
 
One sample of each of the sponges Petromica citrina (PC), and Chelonaplysilla erecta (CE) 
were collected at Saco do Poço (23453S; 45158W), and Ilha de Serraria (23484S; 45134W) at Ilha 
Bela region, São Paulo State, Brazil, at depths between 5 and 15 m. The sponges were placed in 
sterilized polyethylene bags containing seawater and immediately transported to the Centro de 
Biologia Marinha (CEBIMar) of the Universidade de São Paulo. Sponge samples were washed 
twice with sterilized seawater, cut into pieces and then thoroughly homogenized in a sterile mortar 
with sterile seawater. Triturated samples were diluted in hundred-fold series (10-2, 10-4) and aliquots 
of 100 µL were inoculated into Petri dishes containing the media: TSA Agar (Difco, USA), Marine 
Agar (DifcoTM, USA) and M1 (soluble starch 10 g/L, yeast extract 4 g/L, peptone 2 g/L, agar  
15 g/L). All media were prepared with artificial seawater (ASW): KBr 0.1 g/L, NaCl 23.48 g/L, 
MgCl2.6H2O 10.61 g/L ,CaCl2 .2H2O 1.47 g/L, KCl 0.66 g/L 1, SrCl2 .6H2O 0.04 g/L, Na2SO4 3.92 
g/L, NaHCO3 0.19 g/L, H3BO3 0.03 g/L. Cycloheximide (50 µg.mL
-1) and nalidixic acid  
(15 µg.mL-1) were added to inhibit fungal and many fast-growing Gram-negative bacteria, 
respectively. Agar plates were incubated at 25 ºC and different colonies were isolated from the 2nd 
to the 30th day of plating. Pure cultures were obtained after serial transfers to the same culture 
medium used to plate the sponge samples. The maintenance of the isolates was performed by 
cryopreservation at -80 ºC (10% glycerol). 
The strains were cultured in Nutrient Broth (NB) (Difco) for 24-48 h at 28 °C and genomic DNA 
was extracted from each strain [21]. From the genomic DNA, 16S rRNA gene sequences were 
amplified by polymerase chain reaction (PCR) using bacterial universal primers p27f e p1401r [22] 
and sequencing [23]. 
3. Results 
The antiviral activity of each extract was evaluated initially in a standard titer assay where the 
extracts at nontoxic concentrations were added at the same time as the virus. This initial analysis 
identified which among the many extracts tested have antiviral activity against the virus. The results 
were considered promising if they showed a protection percentage of at least 90% and active if the 
result was higher than 97%. 
One hundred twenty-eight extracts were tested, of wich two were active against the virus. This 
represents 1,5% of the total. One of them was considered promising. The Table 1 summarizes the 
information about the best results. 
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Table 1.General characteristics of the extracts evaluated for antiviral activity. 
 
Extract Sponge Genbank Access number Identification Inhibition percentage (%) 
B511 Chelonaplysilla erecta HQ433229 Exiguobacterium sp. 33 
B515 Chelonaplysilla erecta HQ433231 Vibrio sp. 25 
B555 Petromica citrina Deposit number in process Bacillus sp. 98 
B565 Petromica citrina Deposit number in process Bacillus sp. 37 
B584 Petromica citrina Deposit number in process Bacillus sp. 98 
B616 Petromica citrina Deposit number in process Bacillus sp. 90 
Characteristics of the extracts evaluated for antiviral activity. Name of the each extract evaluated, sponge from which the microorganism was obtained, 
Genbank access number, identification of the microorganism from which the extract was obtained, and inhibition percentage obtained on antiviral 
assay
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3.1. The potential stage in the viral infection cycle 
 
To identify the stage of viral replication cycle on which the active extracts could be operating, three 
different treatments were carried out. The cells were infected with virus followed by addition of the 
extract after 1 h, to evaluate the viral replication phase; viruses were pretreated with the extract before 
infecting the cells (virus inactivation); while addition of the extract to the cells before viral infection 
was performed to evaluate any effect in terms of viral adsorption. In all experiments the extract was 
used at its MNTC. The potential stage in the viral infection cycle for each promising and active extract 
is shown in the Table 2.The MNTC, CC50, IC50 and SI of the active and promising extracts against 
BVDV were calculated and the results are listed in table 2. 
 









B555 >500 >500 27,35 >18 Pretreatment: Adsorption 
B584 150 277 10,24 27 Pretreatment: Adsorption 
B616 1000 1500 47 30,6 Pretreatment: Adsorption 
Characteristics of the promising and active extracts. The active extracts are 555 and 584, and the 
promising extract is 584. The maximum nontoxic concentration (MNTC), antiviral concentration 50% 
(EC50), the 50% inhibition (IC50), the selective index (SI) and the potential stage in the viral infection 
cycle of antiviral action. 
 
According to these results, the three extracts showed SI greater than 4, which ensures its viability in 




The exploration of the marine environment represents a promising strategy in the search for active 
compounds against infectious diseases [1]. This environment is still underexplored in Brazil, despite its 
large size and enormous diversity of species.  
Besides its peculiar structures, marine natural products have an extraordinary diversity of molecular 
targets with expressive selectivity. This greatly increases the pharmacological and therapeutic potential 
of these molecules [24]. 
Marine sponges are among the richest sources of pharmacologically active products derived from 
marine organisms by their secondary metabolites and also by substances produced by their associated 
microorganisms. There are already known more than 5300 products that represent possible alternatives 
against diseases of bacterial, viral, fungal and parasitic origin [25]. 
Bacteria that gave rise to extracts evaluated in this study were isolated from marine sponges 
Petromica citrina and Chelonaplysilla erecta. The marine sponge Petromica citrina is endemic in the 
country. Previously, antimicrobial activity against some resistant bacteria from aqueous extracts of this 




sponge has been demonstrated [26]. However, here, we only isolated active extracts of microorganisms 
from this sponge.  
From the sponges, bacteria were isolated, Vibrio sp. and Bacillus sp., and the extracts obtained from 
them were evaluated against BVDV. Three of these Bacillus generated two active extracts  
(B555 and B584, IP=98%) and one promising (B616, IP=90%) against BVDV. These microorganisms 
were identified as Bacillus sp. These extracts showed SI greater than 4, which ensures its viability on 
in vitro assays. 
Several activities have been described in relation to Bacillus sp. Studies showed that bacteria of this 
genus can devote more than 3% of its genome to genes related to the biosynthesis of secondary 
metabolites [27].  
The experimental study of antiviral activity of spore-forming bacterium Bacillus pumilus 
"Pashkov", carried out in 2010, showed for the first time effective antiviral activity of cultural fluid 
that opens perspectives for development of medications against enterovirus infections [28]. 
The Bacillus intermedius RNAse showed antiviral activity in guinea-pigs and rabbits infected with 
outdoor rabies virus. The intramuscular injection of RNAase failed to protect the infected animals [29]. 
This Bacillus intermedius RNAse previously showed antiviral activity in experiments with mice 
preinfected with street rabies virus [30]. 
A ribonuclease (RNase) with tobacco mosaic virus inhibition was isolated and purified from 
Bacillus cereus. The inhibitory activity of the RNase in the purification process against tobacco mosaic 
virus was tested, and the percentage inhibition of the purified RNase reached 90% [31]. 
Besides antiviral activity, Bacillus species have had several other activities described. 
One study shows the Antiplasmodial activity of bacilosarcin A isolated from the octocoral-
associated bacterium Bacillus sp. collected in Panama. The antiplasmodial activity of the isolated 
compounds was evaluated in vitro against the chloroquine-resistant Plasmodium falciparum strain W2 
and this study constitutes a new addition to the few existing antiplasmodial metabolites isolated from 
heterotrophic bacteria associated with corals, showing that bacteria associated with marine 
invertebrates represents a promising resource for antimalarial research  [32]. 
Another study showed the antibacterial and anticancer activity of ε-poly-L-lysine (ε-PL) produced 
by a marine Bacillus subtilis. The bacterium produced an active compound against a number of gram 
negative bacteria [33]. 
Already been demonstrated, yet, antifungal activity of Bacillus coagulans against Fusarium sp. 
[34], the activity of Macrolactin S isolated from Bacillus sp. AT 28 that inhibited the growth of S. 
aureus, Bacillus subtilis, and Escherichia coli [35], and the antimicrobial activity of Bacillus sp. strain 
FAS1 isolated from soil was demonstrated on the standard indicator species [36]. 
Therefore, this genus represents a rich source of bioactive substances and, according to the obtained 
results, can lead to the development of a new treatment option against HCV infection. 
The preliminary tests of mechanism of action showed that the active extracts (B555 and B584) and 
the promising extract (B616) acts by inhibiting virus adsorption to cell, thus interfering with the 
progression of infection. This may result from changes in proteins involved in the interaction between 
the viral envelope and endosomal membrane. 
 
 






The results of the present study provide further evidence for the potential of microorganisms 
isolated from marine invertebrates, that represents a reservoir of pharmacologically active substances. 
From microorganisms isolated from marine sponges, compounds with potential to lead to the 
development of an alternative therapy against HCV infection were identified. Two of them provided 
98% of protection to the cell and their selectivity index was satisfactory. This activity occurred during 
the adsorption of the virus to the cell. Thus, the extract was able to interfere with the progression of 
infection. Further studies are necessary to discover the substance responsible for this activity and this 
substance may lead to the development of an alternative therapy as needed for the population. 
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